The preoperative serum IL-17A concentration was significantly higher in triple negative breast cancer than in luminal breast cancer, i.e. luminal A (P=0.001), luminal B HER2 negative (P=0.003) and luminal B HER2 positive (P=0.018), as shown in Table 4 and illustrated in Figure 5. A significantly higher serum IL-17A concentration was also found in triple negative subtype after surgery, during adjuvant treatment, in comparison to luminal A (P<0.001) and luminal B HER2 negative (P=0.001) subtypes, shown in Table 4 and Figure 6. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.